Stock Price Quote

MEDICAMEN BIOTECH LTD.

NSE : MEDICAMEQBSE : 531146ISIN CODE : INE646B01010Industry : Pharmaceuticals & DrugsHouse : Private
BSE536.956.5 (+1.23 %)
PREV CLOSE ( ) 530.45
OPEN PRICE ( ) 530.00
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 909
TODAY'S LOW / HIGH ( )530.00 556.95
52 WK LOW / HIGH ( )356.75 903.5
NSE536.106.6 (+1.25 %)
PREV CLOSE( ) 529.50
OPEN PRICE ( ) 544.90
BID PRICE (QTY) 0.00 (0)
OFFER PRICE (QTY) 0.00 (0)
VOLUME 4435
TODAY'S LOW / HIGH( ) 530.55 555.00
52 WK LOW / HIGH ( )355.45 845
1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 1993
Management Info
Rahul Bishnoi - Chairman - Managing Director
Registered Office

Address 1506,Chiranjiv Tower,43, Nehru Place,
New Delhi,
Delhi-110019

Phone 011-47589500-51

Email info@medicamen.com

Website www.medicamen.com

Registrars Details
Link Intime India Pvt Ltd.
Noble Heights, 1st Floor, Plot NH 2,C-1 Block LSC, Near Savitri Market,Janakpuri,New Delhi
Listing : BSE, NSE

NEWS

23Mar Medicamen Biotech informs about disclo
Medicamen Biotech has informed that it enclosed disclosure under regulat..
23Mar Medicamen Biotech informs about disclo
Medicamen Biotech has enclosed the disclosure under Regulation 29(2) of..
16Mar Medicamen Biotech informs about disclo
Medicamen Biotech has attached disclosure dated March 16, 2024 in Form-D..
08Mar Medicamen Biotech informs about disclo
Medicamen Biotech has informed that it attached disclosure dated March 0..
03Oct Medicamen Biotech informs about closur
In terms of the provisions of the Code of Conduct to Regulate, Monitor a..

Financials

in Millions
QTR Dec 23 ANNUAL 23
Net Profit27.66150.01
Gross Profit 40.09 173.32
Operating Profit 64.15266.09
Net Sales 442.041378.84

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Abbott India (BSE)
peergroup  26643.70 (0.58%)
M.Cap ( in Cr)56616.00
Pfizer (BSE)
peergroup  4473.85 (1.59%)
M.Cap ( in Cr)20466.85
Glaxosmithkline Phar (BSE)
peergroup  2355.75 (2.80%)
M.Cap ( in Cr)39907.83
Concord Biotech (BSE)
peergroup  1494.85 (4.43%)
M.Cap ( in Cr)15638.55
Zydus Lifesciences (BSE)
peergroup  1104.45 (5.00%)
M.Cap ( in Cr)111133.51

Shareholding Pattern

NON-INSTITUTION 55.69%
PROMOTERS 43.21%
MUTUAL FUNDS/UTI 0%
FI/BANKS/INSURANCE 0%
GOVERNMENT 0%
FII 0%

About Medicamen Biotech Ltd.

Medicamen Biotech Ltd. was incorporated in the year 1993. Its today's share price is 536.95. Its current market capitalisation stands at Rs 682.71 Cr. In the latest quarter, company has reported Gross Sales of Rs. 1378.84 Cr and Total Income of Rs.1403.46 Cr. The company's management includes Sanjay Bansal, Suresh Kumar Singh, Ashwani Kumar Sharma, Vimal Kumar Shrawat, Parul Choudhary, Sangeeta Bishnoi, Sumita Dwivedi, Ravi Kumar Bansal, Arun Kumar, Harish Pande, Rahul Bishnoi.

It is listed on the BSE with a BSE Code of 531146 , NSE with an NSE Symbol of MEDICAMEQ and ISIN of INE646B01010. It's Registered office is at 1506,Chiranjiv Tower,43, Nehru PlaceNew Delhi-110019, Delhi. Their Registrars are K FIN Technologies Ltd.-(Karvy Fintech Pvt Ltd.) It's auditors are Ashok Sharma & Associates, Rai Qimat & Associates

© NIRMAL BANG. All rights reserved

Designed , Developed & Content Powered by Accord Fintech Pvt. Ltd.

Open an Account
FOR AFREE *DEMAT & BROKING ACCOUNT

Please fill in the details below

Close X

(Note - You will receive a call from our sales executive)

CLOSE X

RISK DISCLOSURES ON DERIVATIVES

  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to ₹ 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.